Company / Cash & Equivalents
PLIANT THERAPEUTICS, INC. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$45.4M
FY2025
5-year range
$33.7M / $71.2M
FY2021-FY2025
Trend
-36.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 6 years, ranging from $34M in FY2022 to $71M in FY2024.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -2.2%.
Declined from $63M to $45M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +10.5%
- 5-Year CAGR
- -2.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 36.2% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.4M | -36.2% |
| FY2024 | $71.2M | +12.6% |
| FY2023 | $63.2M | +87.7% |
| FY2022 | $33.7M | -34.8% |
| FY2021 | $51.7M | +1.5% |
| FY2020 | $50.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026